Shares of Beta Bionics Inc. (NASDAQ: BBNX) are soaring 19.07% in pre-market trading on Wednesday following the company's impressive third-quarter 2025 financial results, raised full-year guidance, and recent FDA clearance for updates to its iLet Bionic Pancreas System.
The medical device company, specializing in diabetes management technology, reported a narrower-than-expected loss of $0.33 per share for Q3, significantly beating the analyst consensus estimate of a $0.44 loss. Revenue for the quarter came in at $27.3 million, surpassing analyst projections of $23.97 million and representing a robust 63.14% increase from $16.7 million in the prior-year period. Beta Bionics' strong performance was driven by impressive growth across its sales channels, with Durable Medical Equipment (DME) channel net sales reaching $21.0 million and Pharmacy Benefit Plan (PBP) channel net sales climbing to $6.2 million.
In light of these results, Beta Bionics raised its full-year 2025 revenue guidance to over $96.5 million, up from the previous range of $88 million to $93 million. The company also increased its estimated gross margin forecast for the year to 54-55%. Adding to the positive momentum, Beta Bionics announced that it received Special 510(k) clearance from the FDA on September 29, 2025, for updates to its iLet device. Analysts have responded positively to Beta Bionics' strong performance and future outlook, with multiple firms raising their target prices, including Leerink Partners (to $33), Stifel (to $31), Truist Securities (to $32), and Piper Sandler (to $32).
Comments